Toru Ishibashi, Ph.D (he/him/his)

Senior Staff
Shionogi & Co., Ltd., Japan

Toru Ishibashi PhD., I was received a degree from Kyoto University in Japan in 2005. I am working in the development of S-309309, a novel selective inhibitor of MGAT2 as a treatment for obesity at Shionogi & Co., Ltd.. I am in charge of clinical pharmacology. My sepecial is population pharmacokinetics and pharmacodynamics.

Poster(s):

• (530) Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET